Search alternatives:
small decrease » small increased (Expand Search)
dramatic » aromatic (Expand Search)
Showing 601 - 620 results of 2,457 for search '((dramatic decrease) OR (small decrease))', query time: 0.17s Refine Results
  1. 601
  2. 602

    Data Sheet 1_Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.docx by Yohan Seo (773204)

    Published 2025
    “…<p>Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. …”
  3. 603
  4. 604

    Supplementary file 1_Temporal interaction information and laser evoked responses: preliminary results in fibromyalgia patients with small fibers pathology.docx by Livio Clemente (22152382)

    Published 2025
    “…</p>Results<p>Control subjects generally exhibited synergy clusters corresponding to N2 and P2 peaks, whereas patients with fibromyalgia (FM), particularly those with distal denervation, exhibited increased redundancy and decreased synergy.</p>Conclusion<p>Patients with FM and small fiber pathology exhibited an alteration in higher-order integration mechanisms due to a complex interaction between cortical processing of pain and denervation of nociceptive fibers.…”
  5. 605

    <b>FOXP3 influences recruitment and polarization of macrophages via regulating CCL5 in non-small cell lung cancer</b> by Zhihua Ye (20486717)

    Published 2024
    “…<p dir="ltr">Forkhead box P3<b> (</b>FOXP3) plays a key role in the malignant progression of non-small cell lung cancer (NSCLC). However, the regulatory effect of FOXP3 on the biological activity of macrophages in NSCLC has not yet been reported.…”
  6. 606

    Data Sheet 1_Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study.docx by Luigi Liguori (9434405)

    Published 2024
    “…Introduction<p>Immune checkpoint inhibitor (ICI)-based immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has radically changed the management of many types of solid tumors including non-small cell lung cancer (NSCLC). Many clinical trials have demonstrated that ICIs improve the survival and the quality of life of patients with advanced non oncogene NSCLC as compared to standard therapies. …”
  7. 607
  8. 608
  9. 609
  10. 610
  11. 611
  12. 612
  13. 613
  14. 614
  15. 615
  16. 616
  17. 617
  18. 618
  19. 619
  20. 620